Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

It’s the first FDA approval for a pain medication in 25 years. How does the drug work, and who is it for?

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

according to Vertex, and VX-540 was also associated with manageable side effects, mainly minor complaints like nausea, headache, and constipation, with no severe adverse reactions recorded.

Vertex Securities Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 36.49 Crore) operating in Financial Services sector. Vertex Securities Ltd. key ...

CPI expected to have risen 0.3% on the month. McDonald's investors looking for earnings inflection. Elliott takes BP stake.